New research suggests that people who come off new weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt conventional lifestyle plans.
Findings released in a leading medical journal demonstrates that while overweight people often shed a large proportion of their total mass while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such treatments need to be aware of the potential of rapid weight regain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
This pace of regain implies a return to original mass in about one and a half years.
Analyzing Therapies
The analysis, which looked at 37 of studies involving over 9,000 of patients, contrasted the effects of GLP-1 agonists with conventional dieting.
Researchers point out that individuals who shed pounds through lifestyle changes alone generally have a less rapid creep back—around 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Doctors believe the mechanism of the jabs accounts for the heightened regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls appetite.
"Long-term administration of the hormone levels far above than normal could lead to the body to produce less of its endogenous GLP-1, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication means appetite is uncontrolled, making excessive eating much more probable."
A Lifelong Disease?
The NHS suggest the injections for individuals with weight-linked health risks, alongside recommended lifestyle changes.
Many experts argue that, considering the likelihood of relapse, the treatment should be considered ongoing.
This perspective is supported by pharmaceutical companies, who note that the findings "emphasize the long-term nature of obesity," akin to managing conditions like hypertension.
Patient Experiences
People who have stopped the jabs explain a intense resurgence of appetite.
"It felt as if a switch that goes on and you're instantly ravenous," said a patient.
This challenge is exacerbated if individuals have not adopted lasting dietary or behavioural modifications during therapy.
Growing Adoption
Survey data show that a significant number of adults in the UK have used these injections in the past year, with interest being substantial.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, clinicians caution that while these medications are potent agents for weight loss, they are not a permanent fix and long-term success relies on ongoing lifestyle changes.
